XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Share
9 Months Ended
Sep. 30, 2022
Net Loss Per Share  
Net Loss Per Share

13.          Net Loss Per Share

Net loss per share (basic and diluted) was computed by dividing net loss attributable to common stockholders, considering the accretions to redemption value of the redeemable noncontrolling interest, by the weighted average number of shares of common stock outstanding. As of September 30, 2022 and December 31, 2021, outstanding stock options totaling 3,415,729 and 3,324,368,

respectively, and outstanding warrants both totaling 617,277, were anti-dilutive, and therefore, were not included in the computation of weighted average shares used in computing diluted loss per share. Pursuant to the reverse stock split, net loss per share was adjusted retrospectively.

The following table sets forth the basic and diluted net loss per share computation and provides a reconciliation of the numerator and denominator for the periods presented:

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

(In thousands, except share and per share data)

2022

2021

 

2022

2021

 

Numerator:

    

  

    

    

  

    

Net loss attributable to CASI Pharmaceuticals, Inc.

$

(5,201)

(10,224)

$

(21,477)

$

(31,053)

Denominator:

 

 

Weighted average number of common stock

 

13,606,130

13,979,636

 

13,668,553

 

13,486,024

Denominator for basic and diluted net loss per share calculation

 

13,606,130

13,979,636

 

13,668,553

 

13,486,024

Net loss per share

 

  

 

  

— Basic and diluted

$

(0.38)

$

(0.73)

$

(1.57)

$

(2.30)